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Abstract
Background: The first wave of pandemic influenza A(H1N1)2009 (pH1N1) reached New South Wales (NSW), Australia in May
2009, and led to high rates of influenza-related hospital admission of infants and young to middle-aged adults, but no
increase in influenza-related or all-cause mortality.
Methodology/Principal Findings: To assess the population rate of pH1N1 infection in NSW residents, pH1N1-specific
haemagglutination inhibition (HI) antibody prevalence was measured in specimens collected opportunistically before
(2007–2008; 474 specimens) and after (August–September 2009; 1247 specimens) the 2009 winter, and before the
introduction of the pH1N1 monovalent vaccine. Age- and geographically-weighted population changes in seroprevalence
were calculated. HI antibodies against four recent seasonal influenza A viruses were measured to assess cross-reactions. Pre-
and post-pandemic pH1N1 seroprevalences were 12.8%, and 28.4%, respectively, with an estimated overall infection rate of
15.6%. pH1N1 antibody prevalence increased significantly - 20.6% overall - in people born since 1944 (26.9% in those born
between 1975 and 1997) but not in those born in or before 1944. People born before 1925 had a significantly higher pH1N1
seroprevalence than any other age-group, and against any seasonal influenza A virus. Sydney residents had a significantly
greater change in prevalence of antibodies against pH1N1 than other NSW residents (19.3% vs 9.6%).
Conclusions/Significance: Based on increases in the pH1N1 antibody prevalence before and after the first pandemic wave,
16% of NSW residents were infected by pH1N1 in 2009; the highest infection rates (27%) were among adolescents and
young adults. Past exposure to the antigenically similar influenza A/H1N1(1918) is the likely basis for a very high prevalence
(49%) of prepandemic cross-reacting pH1N1 antibody and sparing from pH1N1 infection among people over 85 years.
Unless pre-season vaccine uptake is high, there are likely to be at least moderate rates including some life-threatening cases
of pH1N1 infection among young people during subsequent winters.
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Introduction
The first wave of infection due to pandemic influenza A (H1N1)
2009 - pH1N1 - in Australia began in May, 2009 [1]. There was
debate as to whether pH1N1 infections were significantly more
prevalent or severe than during an ‘‘average’’ influenza season [2].
Most clinical infections were apparently mild and predominantly
affected school children and young adults. Increased numbers of
laboratory-confirmed and notified cases, compared with average
influenza seasons, could be partly explained by much greater levels
of public awareness, medical consultation and laboratory testing
[3]. Despite a disease profile generally similar to that of seasonal
influenza, pH1N1 infections led to unusually high rates of hospital
and intensive care unit (ICU) admissions of relatively young
patients with influenza-related illness. ICU admissions for viral
pneumonitis were 15 times higher than in previous years and
highest in the 25–49 year age-group; 93% of ICU patients were
under 65 years [4]. In New South Wales (NSW), the most
populous Australian state, syndromic surveillance of emergency
department presentations showed unusually high rates of febrile
respiratory illness during the 2009 winter but there was neither an
increase in deaths attributable to influenza or pneumonia, nor in
overall mortality [3].
It is difficult to estimate the true rates of pH1N1 infection or
differences between geographic areas and age-groups from limited
epidemiological data, but information about population preva-
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distribution policy and planning for subsequent waves of pH1N1
infection. Serosurveys are used extensively to supplement
laboratory notification, hospitalisation and mortality data for
many vaccine preventable diseases [5].
The aim of this study was to determine the prevalence of
subtype-specific influenza A pH1N1 haemagglutination inhibition
(HI) antibodies in a broadly-based sample of children and adult
residents of NSW, before and after the first pandemic wave, using
opportunistically collected plasma or serum specimens.
Methods
Specimens
Clinical chemistry laboratories in NSW were asked to provide
serum or lithium heparin-treated plasma specimens which had
been submitted for diagnostic testing in August or September,
2009 and would otherwise have been discarded. This period was
3–11 weeks after the first epidemic wave peaked in NSW and
before the monovalent pH1N1 vaccine became available. The
sample size was calculated to provide power to detect a difference
in seroprevalence of 10–15% between age groups with a worst
case 95% confidence interval of 67%. We aimed to test
approximately equal numbers of specimens from NSW residents
in each of seven age-groups (children: preschool 0–4 years,
primary school 5–11 years, secondary school 12–17 years; and
adults: 18–34, 35–64 and 65–85 years and 85 years and older),
providing a total sample size of ,1200 specimens. Specimens
which represented both urban and rural NSW populations were
retrieved using postcode of residence. Specimens were given a
unique identifying code and then de-identified; only the sex, age or
date of birth and patient postcode were recorded.
To estimate the level of pre-existing antibodies to pH1N1, we
also tested stored sera from NSW residents which had been
submitted for non-influenza serological testing during 2007 and
2008. The sample size for prepandemic sera was determined
largely by availability but we aimed to test approximately 50 in
each age-group.
The specimens used for testing had been submitted for
diagnostic testing and would otherwise have been discarded.
Consistent with longstanding practice in the performance of
national serosurveys, informed consent was not obtained from
subjects for the use of their specimens in this study. However, all
specimens were deidentified before testing and only the age or date
of birth and address postcode were recorded. This study, including
the waiver of informed consent, was approved by the Sydney West
Area Health Service Human Research Ethics Committee.
Antigens
The antigen used for HI testing was a gamma-irradiated
preparation of influenza A/California/07/2009 (pH1N1) virus,
provided by the WHO Collaborating Centre for Reference and
Research on Influenza, Melbourne, Australia. Antigens derived
from four recent seasonal influenza A viruses – Brisbane/59/
2007/H1N1, New Caledonia/20/1999/H1N1, Brisbane/10/
2007/H3N2, and Wisconsin/67/2005/H3N2 - were used to
determine levels of antibody to these viruses in the same
specimens.
Haemagglutination inhibition (HI) assay
A pH1N1 subtype-specific HI assay was developed using
established methods. As initial evaluation demonstrated that
lithium heparin used as anticoagulant did not significantly affect
antibody titres in plasma (compared with serum) whereas EDTA
plasma specimens gave less consistent results, only lithium
heparin-treated plasma and serum specimens were used.
Briefly, specimens were diluted 1/5 in Vibrio cholerae receptor
destroying enzyme and incubated overnight at 37uC to remove
inhibitors, then diluted 1/2 in citrate and heat inactivated at 56uC.
Serial doubling dilutions (and appropriate controls) were reacted
with antigens in 96-well V-bottom microtitre trays for 1 hour at
room temperature before a 1% v/v suspension of human group O
red blood cells was added. After 1–2 hours (or when the cell
control had fully haemagglutinated), endpoints were read by two
independent operators as the last dilution showing complete
inhibition of haemagglutination. Titres of $40 were determined to
be ‘‘positive’’ for the purpose of this serosurvey.
Statistical analysis
Geometric mean titres (GMTs) were calculated by assigning a
titre of 5 to specimens in which no HI antibody was detected
(titre,10). Seroprevalence of pH1N1 antibodies was calculated as
the percentage with antibody titres$40, after weighting for age,
sex and geographic region.
The post-pandemic sample size was designed with a dispropor-
tionately greater representation of very young and very old persons
and with broad coverage of all geographic areas of NSW by using
postcode as a stratification variable. As postcodes in NSW are not
grouped geographically, there was some disproportionate repre-
sentation by region. The initial design of the sample required
design weights to be calculated to account for the non-uniform
probability of selection between age and postcode strata.
In order to compensate for under- and over-sampling from
sections of the NSW population, post-stratification weights for
both the pre- and post-pandemic samples were also created to
balance the sample by five-year age group and by geographic
region [6]. Post-stratification weights were calculated using raking
since the number of cases in each post-stratification cell was small
[7,8,9]. Geographic regions were defined using 2006 Australia
Standard Geographic Classification of the Australian Bureau of
Statistics (ABS) [10]. Statistical Subdivisions within Sydney and
Statistical Divisions outside Sydney were used to define the
regions. Socioeconomic status was assigned based on the postcode
of residence and therefore indicates the socioeconomic status of
area of residence not the individual. Socioeconomic status was
classified using the Index of Relative Socioeconomic Disadvantage
from the Socio-Economic Indexes for Areas (SEIFA) developed by
the ABS [11].
Differences in weighted proportions were tested using the Rao-
Scott Chi-square test. Confidence intervals for differences in
proportions between the pre-pandemic and post-pandemic
samples were estimated using bootstrapping with 10,000 replica-
tions [12]. Odds ratios were calculated using weighted bivariate
logistic regression. SAS version 9.1.3 (SAS Institute Inc., Cary,
NC) was used for all weighting and statistical analysis.
Results
Pre- and post-pandemic seroprevalence by birth cohort/
age-group
A total of 474 ‘‘pre-pandemic’’ specimens collected in 2007–
2008 were tested. Antibodies were detected at titres of $40 in only
one of 53 from children born in 1998 or later. Overall, 12.8% of
patients had pre-existing pH1N1 antibody at titres$40. Differ-
ences in pre-pandemic prevalence of pH1N1 antibody titres$40
across the five youngest birth-cohorts (born after 1944), were not
statistically significant but the pre-pandemic prevalence was
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in those born before 1925 (Table 1).
A total of 1247 ‘‘post-pandemic’’ specimens collected in August
and September 2009 were tested. The overall prevalence of
pH1N1 antibody titres$40 in the NSW population, after the first
wave of pH1N1 infection, was 28.4% (females 29.0%, males
27.7%; difference not significant). Post-pandemic seroprevalence
was highest in those born in the periods 1975–1991 (40.1%),
1992–1997 (40.0%) and pre 1925 (49.4%; Table 1).
The overall increase in seroprevalence between pre- and post-
pandemic periods was 15.6% and differences were statistically
significant in birth cohorts after 1944 (those aged less than 65
years; 20.6% change overall), and greatest in the 1992–1997 (aged
12–17; 34.5% change) and 1975–1991 (aged 18–34; 24.3%
change) birth cohorts. The increase did not reach statistical
significance in the 0–4 and 5–11 age-groups, separately, but when
these two groups were combined the increase, from 1.6% (95% CI
0.0–4.7) to 13.7% (95% CI 9.9–17.6); difference 12.1% (p=0.006,
Rao-Scott Chi squared test) was highly significant. Apparent
decreases in seroprevalence in the 1925–44 and pre-1925 birth
cohorts (65–85 and $85 year age-groups) were not statistically
significant (Table 1, Figure 1).
Geographic and socioeconomic differences in pH1N1
seroprevalence
Seroprevalence of pH1N1 antibodies in pre- and post-pandemic
specimens were compared between the Sydney region (estimated
resident population 4.5 million) and the rest of NSW (population
2.6 million, spread over a very large geographic area; Table 2).
There was no significant difference in seroprevalence between
regions in pre-pandemic specimens, but the difference in pH1N1
seroprevalence between pre- and post-pandemic specimens was
significantly higher in Sydney than in the rest of NSW (19.3% vs
9.6%, Table 2).
Results were also analysed by accessibility/remoteness index of
Australia (ARIA+) categories. Seroprevalence was highest (30.2%)
in the most accessible (urban) region, but differences by
accessibility classification were not significant (p=0.30). Finally,
seroprevalence was compared across socioeconomic indices for
areas (SEIFA) quintiles, based on postcode of residence.
Seroprevalence varied from 25.5% to 33.3% by socioeconomic
status, but differences were not statistically significant (p=0.58).
Levels of antibodies to pH1N1 and other recent seasonal
influenza A viruses
In addition to pH1N1 antibody, subtype/strain-specific HI
antibodies against four recent seasonal influenza A virus antigens
were measured in postpandemic specimens. The highest sero-
prevalences (at titres$40) for different viruses were in different
age-groups/birth cohorts: 5–11 (1998–2004) and 12–17 year olds
(1992–1997) for Brisbane/59/2007/H1; 5–11 (1998–2004), 12–17
(1992–1997) and 18–34 year olds (1975–1991) for New Caledo-
nia/20/1999/H1; 12–17 (1992–1997) for Wisconsin/67/2005/
H3 and 5–11 (1998–2004) for Brisbane10/2007/H3. There were
significant differences in seroprevalence and GMTs across age
groups for each of the five viruses (Table 3).
The proportions of specimens with HI antibody titres$40
against seasonal influenza A subtypes were compared for
specimens with pH1N1 antibody titres$40 vs ,40 (Table 4).
There was no significant relationship between the presence or
absence of pH1N1 antibody and that of any seasonal influenza A
virus antibody, except that samples in which pH1N1 antibody was
detected were less likely to have Brisbane/59/2007/H3 antibody
than pH1N1 antibody negative samples; this difference was just
statistically significant (odds ratio 1.8; p=0.05).
Discussion
During the southern hemisphere winter of 2009, in Australia,
the pH1N1 epidemic period lasted about 18 weeks in all [1,3].
However, there were considerable variations in rates of spread,
numbers of laboratory-confirmed cases, timing of epidemic peaks
and rates of hospital and ICU admission between and within
different States and major cities [1,3,4]. Most cases apparently
occurred in school-aged children and were mild and generally not
laboratory-confirmed. Hospital admission rates were highest in the
Table 1. Comparison of prevalence of haemagglutination inhibition assay titres$40 against influenza A California/07/2009
(pH1N1) collected in pre- and post-pandemic periods, New South Wales, Australia, by year of birth cohort.
Year of birth cohort Prepandemic (2007–8) Postpandemic (August–September 2009)
Population change
in seroprevalence
(95% CI
2)
Tested Titre$40 GMT
Weighted percent
1
(95% CI) Tested Titre$40 GMT
Weighted
percent
1(95% CI)
2005 or after 20 0 5.2 0.0% 207 36 9.6 15.6% (9.9–21.4) 15.6% (10.5–22.4)
3
1998–2004 33 1 5.3 2.6% (0.0–7.6) 170 27 9.9 12.4% (7.3–17.5) 9.8% (0.0–15.9)
3
1992–1997 47 6 5.9 5.5% (0.6– 10.4) 176 73 22.9 40.0% (31.0– 49.1) 34.5% (24.0–44.7)
3
1975–1991 95 12 8.9 15.8% (5.5– 26.0) 229 91 23.0 40.1% (32.7– 47.5) 24.3% (9.6–35.5)
3
1945–1974 143 9 8.2 6.7% (1.2– 12.2) 231 62 15.4 26.3% (19.8– 32.7) 19.6% (10.1–27.5)
3
1925–1944 71 26 15.2 33.5% (20.2– 46.8) 171 37 16.9 19.9% (12.9– 26.9) 213.4% (230.2–+0.3)
Pre 1925 65 39 33.1 62.3% (49.4–75.2) 63 31 31.8 49.4% (34.5–64.2) 212.9% (232.9–+6.7)
Total sample 474 93 8.6 12.8%(8.9–16.6) 1247 357 16.7 28.4% (25.0–31.7) 15.6% (10.2–20.4)
CI=confidence interval.
Notes:
1Weighted by age and geographic region.
2Bootstrap bias-corrected and accelerated confidence intervals.
3Statistically significantly (p,0.05).
doi:10.1371/journal.pone.0012562.t001
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average influenza season among adults over 60 years [3]. Around
one third of patients admitted to ICU with pH1N1 influenza-
related illness had no underlying risk factors, most required
mechanical ventilation and at least 14% died [4].
In view of these unusual features, estimates of true infection rates in
different age-groups and geographic areas are needed to inform
immunisation policy and planning for the predicted second wave of
infection. Clinical and epidemiological data alone are inadequate,
since mild or asymptomatic infections were not recorded and the
clinical presentation and rates vary in different age groups.
Laboratory diagnostic strategies also varied across States and at
different times within the pandemicperiod. Although pH1N1was the
most common influenza virus detected, seasonal influenza A/H3N2
and A/H1N1 (and other respiratory viruses) were circulating at the
same time, at least early in the pandemic [13]. A seroprevalence
survey, encompassing all age-groups and geographic areas, is a timely
and practicable source of more comprehensive data.
Influenza A serosurveillance is complicated by cross-reactions
between different influenza A subtypes, variable and often
relatively short-lived influenza antibody responses, repeated
previous infections and the technical challenges of HI and viral
neutralization assays [14]. We have shown previously [5] that,
despite some theoretical disadvantages, the opportunistic sampling
strategy used in this study can produce results comparable with
those from randomly collected samples (which also have
disadvantages) for serosurveillance of many vaccine-preventable
diseases. To improve representativeness of this sampling strategy,
we employed an age- and geographically-based sampling frame for
the post-pandemic sera, and adopted post-stratification sampling
weights to achieve better representation of the NSW population
structure. This serosurvey is the first reported from the southern
hemisphere, where the pH1N1 epidemic coincided with the usual
winter influenza and respiratory virus season. The results
confirmed many of the epidemiological features of this outbreak
as shown by notification and hospitalisation data.
Genomic and proteomic studies show that pH1N1 is most like
the North American swine A/H1N1 and pandemic A/
H1N1(1918) viruses and distinct from recent seasonal A/H1N1
and other 20
th century pandemic influenza A viruses [15,16,17].
Host-specific genomic signatures of pH1N1, which are mainly
swine-like, show a high level of identity with influenza A/
H1N1(1918). Since the beginning of the 2009 pandemic, some
mutations have occurred in functional viral genes, which may
Figure 1. Prevalence of antibody to pandemic influenza A (H1N1) 2009. Data are percentages of subjects with H1N1 haemagglutinating
antibody titres$40, in pre- and post-pandemic samples, from New South Wales residents by age group.
doi:10.1371/journal.pone.0012562.g001
Table 2. Comparison of prevalence of pH1N1 antibody titres$40 in specimens collected in pre- and post-pandemic periods from
residents of Sydney and the rest of NSW.
Region Pre-pandemic (2007–8) Post-pandemic (2009)
Change in seroprevalence
(95% CI)
1 p-value
2
Tested Titre$40 GMT Percent (95% CI) Tested Titre$40 GMT Percent (95% CI)
Sydney 300 61 8.3 11.7 (7.1–16.3) 826 249 17.7 31.0 (26.6–35.5) 19.3% (12.3–25.3) 0.0001
Rest of NSW 174 32 9.0 14.5 (7.7–21.4) 421 108 15.2 24.1 (19.1–29.1) 9.6% (0.0–17.2) 0.0438
Total 474 93 8.6 12.8 (8.9–16.6) 1247 357 16.7 28.4 (25.0–31.7) 15.6% (10.2–20.4) 0.0001
Notes.
1Bootstrap bias-corrected and accelerated confidence intervals.
2Rao-Scott Chi-square test. Numbers are weighted by age and region.
doi:10.1371/journal.pone.0012562.t002
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there is no evidence of antigenic change [17].
Similarities between pH1N1 and influenza A/H1N1(1918) have
been reflected in a number of surveys of sera collected before the
2009 pandemic [16,18,19]. Few, if any, children and fewer than
10% of young adults had cross-reacting pH1N1 neutralising
antibody at titres$40 whereas at least one third of adults aged
.65 years had significant titres. While seasonal influenza
vaccination produced many-fold increases in GMT of seasonal
A/H1N1 antibodies it resulted in a modest, two-fold increase in
GMT of cross-reactive pH1N1 antibody in young adults and none
in children or adults $60 years [18,19]. These results are
consistent with other evidence that pH1N1 and seasonal A/
H1N1 are antigenically different, but suggest that, nevertheless,
seasonal H1N1 vaccination may boost low levels of pre-existing,
cross-reactive pH1N1 antibody.
This is supported by the results of a serosurvey in an
unvaccinated population in southern China, in which no cross-
reacting pH1N1 antibody was detected in prepandemic sera in
subjects aged $60 years, in a largely unimmunised population;
pH1N1 antibody levels did not increase after administration of
seasonal influenza vaccine. The authors suggested that the
presence of cross-reactive pH1N1 antibody in western populations
could be due to repeated seasonal influenza vaccination, rather
than exposure to older, seasonal H1N1 influenza viruses [19], as
suggested previously [20].
The significantly higher proportions of subjects over 85 years
with cross-reacting antibodies in pre-pandemic specimens in our
study, are consistent with results of recent studies from England
and Finland [21,22]. In England, the proportion of samples with
cross-reacting HI antibodies with titres$1:32 ranged from 1?8% in
children aged 0–4 years to 31?3% in adults aged 80 years or older.
The trends were similar in Finland, where 96% of people born
before 1919 (at least 90 years old) had cross-reacting pH1N1
antibodies, compared with 14–77% of those born between 1920
and 1944 and very few of those born since 1944. It is likely that A/
H1N1(1918)-like viruses were the first influenza A viruses to which
many individuals born during or before the 1920s were exposed
and that repeated exposure, subsequently, to seasonal influenza A
viruses and/or vaccines, has boosted immunity to A/H1N1(1918)
and hence cross-reactive immunity to pH1N1. This would account
for the sparing of these age-groups from significant levels of
influenza infection during the current pandemic.
We demonstrated an overall increase in the seroprevalence of
pH1N1 antibodies with titres$40 (corresponding with infection
rates) of nearly 16% in NSW residents following the southern
hemisphere 2009 winter. Increases were restricted to age-groups
less than 65 years, particularly the 12–17 (1992–7 birth cohort)
and 18–34 (1975–91) year age groups with increases of 34.5% and
24.3%, respectively. In a similar study, Miller et al showed
comparable age-related differences in seroprevalence increases in
London and the West Midlands, where infection rates were
Table 3. Proportion with subtype-specific HI antibodies and geometric mean titres against five different influenza A subtypes in
specimens collected in August/September 2009, New South Wales, Australia, by age-group.
Influenza A virus subtype
Year of
birth cohort
No.
tested
California/07
2009/H1 (pH1N1)
Brisbane/59
2007/H1
New Caledonia/20/
1999/H1 Wisconsin/2005/H3
Brisbane/10
2007/H3
Titre$40
n (%) GMT
Titre$40
n (%) GMT
Titre$40
n (%) GMT
Titre$40
n (%) GMT
Titre$
40 n (%) GMT
2005 onwards 207 36 (16) 9.6 17 (7) 7.9 9 (4) 6.5 10 (5) 7.1 10 (4) 6.8
1998–2004 170 27 (12) 9.9 67 (38) 21.3 46 (26) 13.4 27 (17) 9.4 38 (19) 9.7
1992–1997 176 73 (40) 22.9 52 (27) 15.3 29 (16) 10.6 41 (19) 10.8 4 (5) 6.3
1975–1991 229 91 (40) 23.0 38 (18) 12.7 34 (16) 11.2 29 (13) 10.0 6 (4) 7.4
1945–1974 231 62 (26) 15.4 19 (8) 9.1 15 (6) 8.3 16 (6) 8.1 9 (4) 7.8
1925–1944 171 37 (20) 16.9 22 (13) 11.2 18 (9) 9.9 28 (16) 14.0 26 (16) 11.8
Pre 1925 63 31 (49) 31.8 8 (10) 11.3 3 (4) 8.1 12 (16) 15.5 8 (11) 10.3
Total 1247 357 (28) 16.7 223 (15) 11.4 154 (11) 9.6 163 (11) 9.5 101 (7) 8.1
GMT=geometric mean titre.
Differences in prevalence of positive titres (using Chi-squared test for trend) and in GMTs (using ANOVA on ‘‘raw’’ titres) between age-groups are statistically significant
for all five virus antigens (p,0.001).
doi:10.1371/journal.pone.0012562.t003
Table 4. Proportions of specimens with HI antibodies (with titres$40) against four seasonal influenza A viruses in pH1N1 antibody
positive (titre$40) and negative samples.
California/07/2009/H1
(pH1N1) result: Brisbane/59/2007/H1 New Caledonia /20/1999/H1 Wisconsin/2005/H3 Brisbane/10/2007/H3
Negative,40 16.3% 11.1% 11.7% 8.0%
Positive$40 12.4% 11.7% 9.7% 4.5%
OR (95% CI); P value 1.38 (0.88–2.19); 0.16 0.95 (0.59–1.52); 0.82 1.23 (0.74–1.21); 0.42 1.80 (1.00–3.32); 0.05
CI=confidence interval; OR=odds ratio.
doi:10.1371/journal.pone.0012562.t004
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areas [21]. In Singapore, seroconversion (or infection) rates in four
adult cohorts were: 29% in military personnel; 13.5% in the
general population; 6.5% in hospital staff and only 1% in long-
term care residents. Older age was associated with reduced
seroconversion rates [23]. In our study, the proportional increase
in seroprevalence (or infection) in the Sydney area (19.3%), was
twice that detected in the rest of NSW (9.6%). In combination with
data from England and Singapore, this indicates – not surprisingly
- that higher infection rates occur in denser populations.
In addition to pH1N1-specific antibodies, we also studied the
prevalence, in post-pandemic specimens, of antibodies to four recent
seasonalviruses, including two A/H1N1 and two A/H3N2 strains. In
general the highest seroprevalence rates and GMTs were in the same
young age-groups, in which pH1N1 antibodies were most prevalent,
althoughtherewassomevariationbetweenstrains.However,amajor
difference was the relatively high seroprevalence of pH1N1 antibody
compared with the other four recent seasonal influenza A viruses in
those aged over 85 years (and to a lesser extent in the 65–85 year
group). This supports the hypothesis that repeated infection by
seasonal influenza A viruses or vaccination boost responses to the first
influenzaAvirustowhichtheseolderpeoplewereexposedwhenvery
young - which is likely to have been A/H1N1(1918)-like viruses -
rather than to more recent seasonal viruses. The proposition that
recent seasonal influenza A virus vaccine can provide modest
protection against pH1N1, despite antigenic differences, has been
suggested previously [20,24,25], but disputed by others [26,27]. Our
observation that there was a small but significant negative association
between the presence of pH1N1 antibodies and seasonal Brisbane/
59/2007A/H3N2 antibodies, in post-pandemic samples, may be a
chance finding but, alternatively, could support this proposition.
In summary, we have shown that the highest rates of infection
were among children over 12 years and young to middle-aged
adults. The elderly were largely spared, confirming clinical and
epidemiological data. As expected, infection rates were higher in
Sydney than in smaller cities and rural areas of NSW. The study
provided evidence of previous exposure to an antigenically similar
influenza A virus in the oldest age-groups (.85 years and 65–85
years). The overall infection rates in NSW indicate that pH1N1
infections are likely to recur with at least moderate frequency in
younger age-groups during the 2010 winter influenza season,
unless there is high pH1N1 immunisation uptake.
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